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creatinine, giving a stronger signal in comparison to that ofCystatin C is a more sensitive marker than creatinine for the
creatinine over the range of the measured GFR. The maximumestimation of GFR in type 2 diabetic patients.
diagnostic accuracy of serum cystatin C (90%) was significantlyBackground. Glomerular filtration rate (GFR) is the best
better than those of serum creatinine (77%) and Cockcroftoverall index of renal function in health and disease. Inulin
and Gault estimated GFR (85%) in discriminating betweenand 51Cr-EDTA plasma clearances are considered the gold
type 2 diabetic patients with normal GFR (80 mL/min perstandard methods for estimating GFR. Unfortunately, these
1.73 m2) and those with reduced GFR (80 mL/min/1.73 m2).methods require specialized technical personnel over a period
In particular, the cystatin C cut-off limit of 0.93 mg/L corre-of several hours and high costs. In clinical practice, serum
sponded to a false-positive rate of 7.7% and to a false-negativecreatinine is the most widely used index for the noninvasive
rate of 1.9%; the serum creatinine cut-off limit of 87.5 mol/Lassessment of GFR. Despite its specificity, serum creatinine
corresponded to a false-positive rate of 5.8% and to a false-demonstrates an inadequate sensitivity, particularly in the early
negative rate of 17.0%.stages of renal impairment. Recently, cystatin C, a low molecu-
Conclusions. Cystatin C may be considered as an alterna-lar mass plasma protein freely filtered through the glomerulus
tive and more accurate serum marker than serum creatinineand almost completely reabsorbed and catabolized by tubular
or the Cockcroft and Gault estimated GFR in discriminatingcells, has been proposed as a new and very sensitive serum
type 2 diabetic patients with reduced GFR from those withmarker of changes in GFR. This study was designed to test
normal GFR.whether serum cystatin C can replace serum creatinine for
the early assessment of nephropathy in patients with type 2
diabetes.
Methods. The study was performed on 52 Caucasian type 2
Diabetic nephropathy is the single most frequent causediabetic patients. Patients with an abnormal albumin excretion
of end-stage renal disease (ESRD) in the United Statesrate (AER) were carefully examined to rule out non-diabetic
renal diseases by ultrasonography, urine bacteriology, micro- and in Europe [1–3], and is predominantly due to type
scopic urine analysis, and kidney biopsy. Serum creatinine, 2 diabetes mellitus. An increasing number of type 2 dia-
serum cystatin C, AER, serum lipids, and glycosylated hemo- betic patients live long enough for nephropathy and
globin (HbA1c) were measured. GFR was estimated by the ESRD to develop, since the treatment of diabetes, hyper-plasma clearance of 51Cr-EDTA. In addition the Cockcroft
tension and coronary heart disease has improved. There-and Gault formula (Cockcroft and Gault estimated GFR) was
calculated. fore, prevention of diabetic renal disease, or at least the
Results. Cystatin C serum concentration progressively in- postponement or slowing down of the disease process,
creased as GFR decreased. The overall relationship between has emerged as a key issue [4, 5]. Microalbuminuria is
the reciprocal cystatin C and GFR was significantly stronger
the first detectable functional abnormality [6]; a propor-(r  0.84) than those between serum creatinine and GFR (r 
tion of microalbuminuric patients then progress to overt0.65) and between Cockcroft and Gault estimated GFR and
GFR (r  0.70). As GFR decreased from 120 to 20 mL/min/ nephropathy, characterized by the presence of protein-
1.73 m2, cystatin C increased more significantly that serum uria [7]. Although measurements in albumin excretion
rate (AER) are very useful in clinical practice, there is
a 40% day-to-day variability in AER [8]. In addition,Key words: cystatin C noninvasive measurement of GFR, glomerular
the efficacy of the therapeutic treatment for diabeticfiltration rate, type 2 diabetes, diabetic nephropathy, serum creatinine,
end-stage renal disease. nephropathy is commonly evaluated by assessing its posi-
tive effects on glomerular filtration rate (GFR), whileReceived for publication March 29, 2001
those on AER alone are not sufficient to prove a clinicaland in revised form October 18, 2001
Accepted for publication October 31, 2001 benefit. Indeed, the rate of the glomerular filtration is
widely believed to be the best overall index of renal 2002 by the International Society of Nephrology
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function in health and disease [9–11]. While inulin and for the early assessment of changes in GFR [27, 28].
One of the most significant advantages of cystatin C in51Cr ethylenediaminetetraacetic acid (51Cr-EDTA) clear-
ances are traditionally considered the gold standard for comparison with traditional markers of renal impairment
is that very small reductions in GFR cause significantmeasuring GFR, they require specialized technical per-
sonnel over a period of several hours [12]. In addition, increases in cystatin C serum levels [29].
This study was designed to compare traditional mark-a number of practical considerations (cumbersome meth-
ods of determination, radioactivity, high costs) have lim- ers of changes in GFR with cystatin C in patients with
type 2 diabetes, and to determine whether diagnosticited the use of these techniques in clinical practice. Serum
creatinine and creatinine clearance are the most widely accuracy of serum cystatin C is better than that of serum
creatinine and Cockcroft and Gault estimated GFR forused indices for the routine noninvasive estimation of
GFR. Serum creatinine is considered relatively specific, the early assessment of diabetic nephropathy.
but not very sensitive since its levels significantly increase
when more than 50% of the GFR is reduced [13]. The
METHODS
serum creatinine concentration may be significantly in-
Patientsfluenced by several extra-renal factors (muscle mass,
changes in tubular secretion, dietary intake, analytical The study was performed on 52 Caucasian type 2 dia-
betic patients (33 males, 19 females, aged between 48interferences, etc.): especially in elderly female patients
with reduced muscle mass, measurement of serum creati- and 73 years) during day-hospital admission in the De-
partment of Medical and Surgery Sciences at Padua.nine may grossly underestimate the reduction in the
GFR. Finally, numerous drugs and endogenous sub- Type 2 diabetes was diagnosed in all patients after age
40 years. The therapeutic treatment consisted of eitherstances also interfere with the measurement of creati-
nine, leading to falsely high or low creatinine values [14]. diet alone or in association with oral hypoglycemic
agents and/or insulin. No patient received insulin overConsequently, there is a need to provide an alternative
method to creatinine that is analytically more reliable the first two years after diagnosis. Hypertensive patients
were treated with angiotensin-converting enzyme (ACE)and as or more clinically reliable. Because the kidney
plays a major role in the metabolism of low molecular inhibitors and/or with calcium channel blockers. When
necessary, diuretics were added. Patients with abnormalmass (low-Mr) plasma proteins, it was postulated that
their serum levels might reflect changes in GFR. Most AER (20 g/min) were carefully examined to rule out
non-diabetic renal diseases by performing ultrasonogra-low-Mr plasma proteins are freely filtered by the glomer-
ulus and then almost completely reabsorbed and catabo- phy, urine bacteriology, microscopic urine analysis, and
kidney biopsy. Renal function was assessed by measuringlized by proximal tubular cells [15, 16]. Among these
proteins, cystatin C has been recently suggested as a urinary AER, serum creatinine, serum cystatin C, and
by determining the 51Cr-EDTA plasma clearance. Weserum marker of changes in GFR. Human cystatin C is
a basic low-Mr plasma protein of 13,359 Daltons [17] also calculated the Cockcroft-Gault formula. Further-
more, levels of hemoglobin A1c (HbA1c), glucose, andwith 120 amino acid residues. It belongs to the cystatin
superfamily [18] and is synthesized and secreted by all plasma lipids [total cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides] were measured to as-nucleated human cells [19]. Cystatin C does not cross
the placental barrier [20] and it does not seem to be sess risk factors for nephropathy [30]. All 52 patients
accepted to participate in the study, giving informedsignificantly influenced by gender and age beyond the
first year of life [21]. Inflammation does not influence consent. The study was approved by the local ethical
committee.serum cystatin C variations, and thus it cannot be consid-
ered an acute phase protein [22]. In healthy adults, cy-
Methodsstatin C reference intervals, assessed by nephelometry,
were found to range from 0.51 to 0.98 mg/L, being inde- Blood pressure was measured by mercury sphygmo-
manometers with the patients standing; the average ofpendent from gender and age [23]. Because of its low-
Mr and its positive charge at physiological pH, cystatin four determinations was recorded, using extra cuff size
if upper-arm circumference exceeded 32 cm. Body massC easily crosses the glomerular filter; after filtration, the
proximal tubular cells reabsorb and catabolize virtually index (BMI, kg/m2) was calculated by dividing weight,
expressed in kg, for height, expressed in meters. Percuta-all of the filtered cystatin C rate [24]. It was demonstrated
that the renal clearance of cystatin C is closely related neous renal biopsies were performed under ultrasound
guidance; tissue was examined under dissecting micro-to GFR, measured as 51Cr-EDTA clearance [25]. Indeed,
the serum concentration of cystatin C increases consider- scope to ensure adequate number of glomeruli and pro-
cessed for light, electron, and immunofluorescent micros-ably in patients with renal failure, as does that of other
low-Mr plasma proteins [26]. Thus, cystatin C has been copy [31, 32]. GFR was estimated by plasma clearance
of 51Cr-EDTA [33]. After a single bolus injection of 1proposed as a new sensitive endogenous serum marker
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mg Ci/kg of 51Cr-EDTA within 30 seconds, 12 venous (ANOVA) followed by the Scheffe´ multiple comparison
test and by the unpaired Student t test. P  0.05 wasblood samples were drawn at 5, 15, 30, 60, 90, 120, 150,
180, 210, 240, 270, and 300 minutes. Finally, the 51Cr considered statistically significant. Reciprocal values of
serum cystatin C and serum creatinine were calculatedradioactivity was measured in duplicate 1-mL aliquots
of plasma in a gamma counter with energy windows set for the correlation with the 51Cr-EDTA clearance. This
procedure resulted in a linearization of the curvilinearto 240 to 400 keV (Cobra-5002 CPM; Camberra Packard,
Milan, Italy). All biochemical examinations were done relationship between renal filtration and the serum
marker concentration. Correlations between variablescentrally and the assays were unchanged during the study
period. Urinary albumin measurements were performed were investigated by using the simple linear regression
analysis and by calculating the coefficient of regressionon three consecutive 24-hour urine collections, after urine
cultures were found to be sterile. Analytical method is (r) [39]. To assess the diagnostic value of the individual
markers, receiver operating characteristic (ROC) werebased on a commercial available nephelometric immuno-
assay [34] on the fully-automated BN II nephelometer obtained and calculated. Non-parametric ROC curves
were generated by plotting the sensitivity versus 1-speci-(Dade Behring, Milan, Italy). The detection limit of the
assay is 8.0 mg/L. Serum cystatin C was measured by a ficity, giving the ideal test a sensitivity equal to 1 and a
specificity equal to 1 (corresponding to 1-specificity equalnephelometric immunoassay based on rabbit monospe-
cific anti-human cystatin C antiserum, covalently coated to zero). The area under the curve (AUC) represents
the most commonly used measure of the diagnostic effi-with 80-nm diameter chloromethylstirene particles [35]
(Dade Behring Diagnostics). Serum creatinine was mea- ciency of a test. Traditionally, this AUC is always 0.5,
values ranging from 1 (ideal perfect separation of thesured by the Vitros enzymatic assay [36] (Vitros 950;
Ortho Diagnostic Division, Milan, Italy). We estimated test values between groups of patients and controls) to
0.5 (no apparent distribution difference between the twoGFR also by applying the Cockcroft and Gault formula
[37]: Cockcroft and Gault estimated GFR (mL/min)  groups). According to Hanley and McNeil [40], we calcu-
(140  age) · weight (kg)/ · serum creatinine (mg/dL), lated areas under the curves, 95% confidence intervals
where age is expressed in years, and  is a constant (0.72 (CI) [41], and differences between ROC curves. A value
in males, 0.85 in females). HbA1c was assessed by HPLC 1.96 of the critical ratio z, defined as z score, was
(BioRad Laboratories, Milan, Italy). Serum glucose was considered significant, as indicated elsewhere [42].
measured by the glucose-oxidase enzymatic method on
a fully-automated multichannel analyzer (Hitachi 200,
RESULTSRoche, Milan, Italy). Total cholesterol and triglycerides
On the basis of the 51Cr-EDTA plasma clearance val-were measured enzymatically on the same fully-auto-
ues, type 2 diabetic patients were divided in two groups:mated multichannel analyzer (Hitachi 200). LDL choles-
28 patients with reduced GFR (80 mL/min/1.73 m2)terol (LDL-c) was determined by using a homogeneous
and 24 with normal GFR (80 mL/min/1.73 m2). Theirmethod for directly measuring serum LDL-c on a fully-
main characteristics are summarized in Table 1. In theautomated analyzer (Hitachi 912, Roche).
group of patients with reduced GFR, 5 patients were
Statistical analysis normoalbuminuric (AER 20 g/min), 5 microalbumi-
nuric (AER 20 to 200 g/min), and 18 macroalbuminuricThe statistical analysis was made by using the MS
(AER200g/min). Among patients with normal GFR,Excel ‘98 software (MicrosoftCo., Seattle, WA, USA),
7 were normoalbuminuric, 11 microalbuminuric, and 6the Astute statistical package (Diagnostic Develop-
macroalbuminuric. Body mass index (BMI) and AERment Unit, University of Leeds, Leeds, UK), and the
significantly differed between the two groups (P 0.01).StatView SE	Graphics 4.01 statistical software (Aba-
A significantly inverse correlation between GFR andcus Concepts Inc., Berkeley, CA, USA) on a Macintosh
AER was found in the overall cohort (r  0.50). ThisPowerBook G3 computer (Apple Computer Inc., Cuper-
inverse correlation was stronger (r  0.60) in patientstino, CA, USA). Results were presented as median (50th
with reduced GFR than in patients with normal GFR (rpercentile), range of measured levels, and percentiles
0.36). In the group with normal GFR, serum creati-[38]. To check the Gaussian distribution, data were pre-
nine values significantly differed (P  0.0001) betweenliminarily evaluated by applying the Kolgomorov-Smir-
males and females (91.7 
 14 mol/L vs. 72.4 
 10nov test, taking P 0.001 as a significant result. Cystatin
mol/L, respectively), while no difference (P  0.21)C and creatinine were found normally distributed; for
was observed for cystatin C values (males, 0.76 
 0.09other variables, we calculated their logarithm before sta-
mg/L; females, 0.72
 0.13 mg/L). Likewise, in the grouptistical treatment. All data were finally evaluated by us-
with reduced GFR we found that serum creatinine valuesing standard parametric tests. In particular, differences
in males (128 
 43 mol/L) significantly differed (P in concentrations of the variables between groups were
investigated by applying the one-way analysis of variance 0.008) from those in females (90 
 13 mol/L), while
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Table 1. Baseline characteristics of patients with type 2 diabetes
GFR
80 mL/min/1.73 m2 80 mL/min/1.73 m2 All patients
(N  28) (N  24) (N  52)
Males/females N 19/9 14/10 33/19
Age years (range) 61 (48–72) 58 (43–73) 59 (43–73)
Duration of the disease years (range) 16.5 (4.0–33.0) 10.5 (1.0–25.0) 14.5 (1.0–33.0)
Body mass index kg/m2 25.5 (19.0–33.0)a 30.5 (20.0–36.0) 28.5 (19.0–36.0)
Mean blood pressure mm Hg 107 (90–140) 107 (90–133) 107 (90–140)
Fasting glucose mmol/L 8.5 (5.5–19.8) 11.0 (6.1–17.1) 10.1 (5.5–19.8)
HbA1c % 7.8 (4.9–11.3) 8.0 (6.0–11.7) 7.9 (4.9–11.7)
Urinary albumin lg/min 386 (3–4524)a 68 (6–1410) 120 (3–4524)
Total cholesterol mmol/L 5.97 (2.69–7.50) 5.49 (3.21–7.58) 5.61 (2.69–7.58)
LDL cholesterol mmol/L 4.11 (1.16–5.71) 3.43 (1.32–6.70) 3.84 (1.16–6.70)
Triglycerides mmol/L 1.50 (0.81–4.27) 1.75 (0.97–5.67) 1.66 (0.81–5.67)
Results are expressed as median values (50th percentile) and ranges, except those referred to the number of males and females.
a Statistical comparison between groups: P  0.01, unpaired Student t test after the logarithmic conversion of data
Table 2. 51Cr-EDTA clearance, serum creatinine, Cockcroft and Gault estimated GFR, and serum cystatin C in type 2 diabetic patients
GFR 80 mL/min GFR 80 mL/min All patients
per 1.73 m2 per 1.73 m2 (GFR: 20–120 mL/min per 1.73 m2)
(N  28) (N  24) (N  52)
51Cr-EDTA clearance 59 97 77
mL/min/1.73 m2 (16–80) (81–137) (16–137)
Serum creatinine 105.6a 79.6a 92.8
lmol/L (70.7–221.0) (61.9–123.8) (61.9–221.0)
Cockcroft and Gault 62b 91b 76
estimated GFR mL/min (24–113) (58–150) (24–150)
Serum cystatin C 1.12c 0.73c 0.89
mg/L (0.78–2.66) (0.54–1.03) (0.54–2.66)
Results are expressed as median values (50th percentile) and ranges.
Statistical comparison between the group of patients with normal GFR and that with reduced GFR: aP  0.001; bP  0.0001; cP  0.00001
serum cystatin C values in the two groups were not sig- estimated GFR and the 51Cr-EDTA plasma clearance
was: Cockcroft-Gault estimated GFR  28.7 	 0.611nificantly different (males, 1.36 
 0.55 mg/L; females,
1.09 
 0.09 mg/L; P  0.07). In patients 61 to 70 years 51Cr-EDTA plasma clearance, r  0.70, 95% CI  70.7
to 80.7. This correlation was found to be substantiallyold, serum creatinine was significantly higher (P  0.02)
than in patients 51 to 60 years old with normal GFR stable in that no difference in the results was observed
between patients with reduced GFR and those with nor-(mean values 92 and 78 mol/L, respectively), while se-
rum cystatin C did not differ between patients of these mal GFR (r  0.46, P  0.01 and r  0.46, P  0.02,
respectively). Furthermore, when the relationship be-two decades (0.74 and 0.76 mg/L, respectively). Table 2
compares the results obtained in the two patient groups tween serum cystatin C and serum creatinine was investi-
gated, the correlation was stronger in patients with re-and in the overall cohort. The overall relationship be-
tween cystatin C (expressed as reciprocal value of the duced renal function (r  0.80, P  0.0001, 95% CI 
0.007 to 0.012) than that in patients with normal renalserum concentration) and GFR was significantly stronger
(r  0.84, P 0.0001, 95% CI 1.05 to 1.15) than those function (r  0.59, P  0.002, 95% CI  0.70 to 0.78).
By comparing the two serum markers, we found that asbetween serum creatinine (expressed as reciprocal value
of the serum concentration) and GFR (r  0.65, P  GFR decreased from 120 to 20 mL/min/1.73 m2, cystatin
C increased more significantly that serum creatinine, giv-0.0001, 95% CI 0.010 to 0.011). Figure 1 makes evident
that the correlation between cystatin C and GFR as well ing a stronger signal in comparison to that of creatinine
over the range of the measured GFR (Fig. 2). In otheras that between serum creatinine and GFR were higher
in patients with reduced renal function (r  0.75, 95% words, by calculating the multiple time of the upper
reference range for both serum markers, cystatin C meanCI  0.80 to 0.93, and r  0.56, 95% CI  0.009 to 0.01,
respectively) in comparison to those with normal or near- values measured for each GFR grouping were always
higher than those of creatinine. Non-parametric ROCnormal renal function (r  0.40, 95% CI  1.29 to 1.45,
and r  0.25, 95% CI  0.011 to 0.013, respectively). plots for serum cystatin C and serum creatinine demon-
strated that area under curve (AUC) of cystatin C (0.954)The overall correlation between Cockcroft and Gault
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Fig. 1. Correlation between 51Cr-EDTA clear-
ance and the reciprocal serum cystatin C con-
centration (A) or between the reciprocal se-
rum creatinine concentration (B) in 52 type 2
diabetic patients.
was significantly greater than that of serum creatinine nine cut-off limit of 87.5 mol/L corresponded to a false-
positive rate of 5.8% (89% specificity) and to a false-(0.812), and than that of Cockcroft and Gault estimated
GFR (0.873), as reported in Figure 3. This was confirmed negative rate of 17.0% (62% sensitivity). A sensitivity
of 100% for serum creatinine and for the Cockcroft andby the statistical comparison between areas, which pro-
vided significant z-score values: 3.37 (95% CI 0.27 to Gault estimated GFR would require cut-off limits (133
and 129 mL/min, respectively) that would yield very low0.013) by comparing cystatin C versus serum creatinine
and 1.98 (95% CI 0.03 to 0.19) by comparing cystatin specificities (29 and 12%, respectively), while a sensitiv-
ity of 100% for cystatin C corresponds to a false-positiveC versus Cockcroft and Gault estimated GFR. The maxi-
mum diagnostic accuracy of serum cystatin C (90%) was rate of 19%. A specificity of 100% for serum creatinine
and the Cockcroft and Gault estimated GFR would re-significantly better than those of serum creatinine (77%)
and Cockcroft and Gault estimated GFR (85%) in dis- quire a cut-off limit (71 and 58 mL/min, respectively)
yielding low sensitivities (12 and 36%, respectively),criminating between the type 2 diabetic patients with a
normal GFR (80 mL/min/1.73 m2) and those with a while a specificity of 100% for cystatin C corresponds
to a false-negative rate of 15%. Table 3 summarizes thereduced GFR (80 mL/min/1.73 m2). In particular, the
cystatin C cut-off limit of 0.93 mg/L corresponded to a ROC analysis results and reports the diagnostic efficien-
cies of the investigated markers in different theoreticalfalse-positive rate of 7.7% (81% specificity) and to a
false-negative rate of 1.9% (97% sensitivity); the creati- conditions.
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Fig. 3. Nonparametric receiver operating characteristic (ROC) plots to
assess the diagnostic efficiency of serum cystatin C (), serum creatinine
(), and Cockcroft and Gault estimated GFR ( ) by distinguishing
between normal and reduced GFR in 52 patients with type 2 diabetes
mellitus.
Fig. 2. Relationship between glomerular filtration rate (GFR), grouped
into six ranges of variation, and proportional changes in cystatin C ()
and creatinine (), both expressed as multiple times of the upper verse correlation between these two indices. However,
reference range. Vertical lines show the standard deviation for the assessment of AER cannot replace the GFR estimation,
distribution of results in each GFR grouping.
because they may represent different aspects of renal
damage. Analysis of data on the basis of gender shows
that the mean concentration was 5.5% higher in males
DISCUSSION than in females for cystatin C (not statistically signifi-
cant). For serum creatinine, this difference was 28%Although cystatin C has been proposed as a reliable
(statistically significant). Because only 4 patients wereserum marker of GFR [21, 23, 24, 27–29], the results in
aged under 50 years and 3 over 70 years, the relationshippatients with diabetes mellitus are controversial. Har-
between the patients’ age and variables was investigatedmoinen et al reported that serum cystatin C is a better
only by comparing two decades (51–60 vs. 61–70 years).marker of GFR than creatinine and creatinine clearance
Despite this limitation, results show that in patients within patients with type 2 diabetes [43], and our results
normal GFR the serum creatinine concentration is sig-confirm these findings. By contrast, Oddoze et al found
nificantly related to age, being 18% higher in patientsthat serum creatinine was better than serum cystatin
aged 61 to 70 than in those aged 51 to 60 years. ByC for the estimation of GFR in microalbuminuric and
contrast, serum cystatin C concentration was 2.7% higherproteinuric diabetic patients [44]. To explain these dis-
in those between 61 and 70 years than between 51 andcordant results, some differences among studies should
60 years. Thus, we can argue that in our patients cystatinbe kept in mind. First, Oddoze et al used only three
C is independent from gender and age, while creatinineblood samples to estimate 51Cr EDTA clearance, the last
is significantly higher in males, as previously describedone at 240 minutes, and therefore their protocol may be
[29], perhaps as a consequence of the different muscleless accurate in assessing GFR than that used in our
mass. This makes serum cystatin C more specific thaninvestigation (12 blood samples over 300 min). Second,
serum creatinine in evaluating renal function. When dataOddoze et al selected a heterogeneous group of type 1
from all 52 patients were included in the calculations,and type 2 diabetic patients, each of them with diabetic
both the serum creatinine and the cystatin C concentra-nephropathy (presence of microalbuminuria or protein-
tions were significantly related to GFR. In Figure 1, theuria), while we studied 12 normoalbuminuric patients.
much tighter distribution of values around the regressionThe decline in renal function in type 2 diabetic patients
line for cystatin C confirms the better correlation be-leads to a reduction in GFR and in a proportional in-
crease of AER, as demonstrated by the significant in- tween cystatin C and GFR with respect to that between
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Table 3. ROC analysis for cystatin C and creatinine as biochemical markers of glomerular filtration in type 2 diabetes mellitus
Positive Negative Diagnostic
Cut-off limit Sensitivity Specificity predictive value predictive value efficiency
Creatinine lmol/L 87.5 62 89 83 73 77a
Cockcroft and Gault
estimated GFR mL/min 75 82 87 88 81 85a
Cystatin C mg/L 0.93 97 81 88 94 90a
Creatinine lmol/L 133 100 29 54 100 61
Cockcroft and Gault
estimated GFR mL/min 129 100 12 57 100 60
Cystatin C mg/L 1.05 100 61 69 100 79
Creatinine lmol/L 71 12 100 100 57 60
Cockcroft and Gault
estimated GFR mL/min 58 36 100 100 57 65
Cystatin C mg/L 0.78 67 100 100 78 85
a Maximum diagnostic efficiency
serum creatinine and GFR. Consequently, cystatin C off level. This difference depends by the choice of the
analytical method for measuring serum cystatin C con-measurement has been shown to be a reliable reflector
of GFR. Cystatin C and creatinine are probably two centration. We measured cystatin C by a nephelometric
immunoassay, and as described elsewhere [35], thisindependent markers of GFR, as described elsewhere
[45]. In fact, they closely correlated in patients with a method significantly differs from the turbidimetric im-
munoassay used previously. Moreover, we calculatedreduced GFR because of being strongly influenced by
renal glomerular impairment, whereas the correlation creatinine clearance by using the Cockcroft and Gault
formula, while in the previous study creatinine clearancewas lower in patients with a normal GFR, as a conse-
quence of different pathophysiological factors that may was traditionally estimated by measuring serum and uri-
nary creatinine. In our study, both when the object is toaffect the serum concentration in that cohort. As shown
in Figure 2, serum cystatin C levels rise earlier and more exclude with certainty type 2 diabetic patients with nor-
mal or near-normal GFR (specificity) and when it israpidly than those of serum creatinine as GFR decreases,
reflecting the greater sensitivity of cystatin C as a pre- important to identify those with GFR impairment (sensi-
tivity), serum cystatin C is a better diagnostic tool thandictor of GFR in type 2 diabetic patients. This greater
sensitivity positively influences the diagnostic accuracy serum creatinine and Cockcroft and Gault estimated
GFR. By analyzing our results, we argue that the poorof cystatin C, as it is significantly higher than that of
serum creatinine and Cockcroft and Gault estimated sensitivity of creatinine may be due to analytical and/or
pathophysiological factors; in other words, this meansGFR, as shown in Figure 3. By using the nonparametric
ROC plot, we describe the alterations in diagnostic sensi- that GFR can change before serum creatinine becomes
abnormal, as found in previous studies [45]. On the othertivity and specificity which occur when the cut-off limit
is gradually increased. Since values of the z-score (3.37 hand, Cockcroft and Gault estimated GFR offers a better
diagnostic efficiency than the traditional creatinine clear-and 1.98, respectively) exceed the limit of 1.96, the AUCs
are significantly different, meaning that the diagnostic ance test; by using a cut-off value of 71 mL/min per
1.73 m2, the previous study found a diagnostic efficiencyaccuracy of the serum concentration of cystatin C is
superior to those of serum creatinine and Cockcroft and that was significantly lower (77%) in comparison to
that found in this study (85%) with a cut-off limit of 75Gault estimated GFR for the assessment of changes in
GFR in type 2 diabetes. The optimum cut-off for cystatin mL/min.
In conclusion, estimation of GFR using an appropriateC—defined as the serum value at which the sum of sensi-
tivity and specificity is greatest—was 0.93 mg/L, that of method is a reliable measure of the kidney function and
impairment in type 2 diabetic nephropathy. Togetherserum creatinine was 87.5 mol/L, and that of Cockcroft
and Gault estimated GFR was 75 mL/min. In a previous with the availability of new, sensitive, non-invasive serum
markers, the accurate estimation of GFR appears to bestudy of 47 type 2 diabetic patients [43], the greatest
diagnostic efficiency for cystatin C was found to be 98%, important because nearly 40% of ESRD patients receiv-
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